CClinicalTrials.gg
CompletedNCT03552315Updated Sep 4, 2019

Effects of a Carbonated Water Enriched With Amino Acids and Chromium Picolinate (Good Idea®) on Glucose Homeostasis.

An interventional study of Carbonated water with amino acids and chromium and Placebo Carbonated Water in Postprandial Hyperglycemia, Metabolic Syndrome and Type 2 Diabetes Mellitus, sponsored by DoubleGood AB. Completed at 1 site in Sweden. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-04.

Sponsored by DoubleGood AB · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

It has previously been shown in healthy subjects, that a carbonated water containing a mix of amino acids and chromium picolinate can decrease postprandial blood glucose. Based on these findings, a flavored sparkling water product called Good Idea® with a proprietary blend of five amino acids and chromium picolinate has been developed. This product, along with an identical placebo, are included in this study to evaluate the effects on postprandial blood glucose in healthy, overweight adults when consumed with a standardized, high glycemic test meal. The study will be conducted in a cross-over design, double-blinded and placebo controlled, including 45 participants. The primary endpoint of the study is the incremental area under the curve (iAUC) for capillary blood glucose within 180 minutes after ingestion of the meal.

02

Conditions studied

  • Postprandial Hyperglycemia
  • Metabolic Syndrome
  • Type 2 Diabetes Mellitus
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's enrollment of 44 is below the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

DoubleGood AB is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or female 18 to 50 years of age
  • BMI 25-29.9 (±0.5) kg/m²
  • Agree to maintain consistent dietary habits and physical activity levels for the duration of the study
  • Healthy as determined by medical history and information provided by the volunteer
  • Willingness to complete questionnaires and follow instructions associated with the study and to complete all visits
  • Has given voluntary, written, informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Elevated fasting blood glucose (at or above 6.1 mmol/L)
  • Women who are pregnant or breast feeding
  • Any medical condition(s) or medication(s) known to significantly affect glucose metabolism. Significance to be assessed by the QI
  • Use of medication, over-the-counter medication, natural health products or dietary supplements/probiotics that may affect glucose metabolism is prohibited during this study. Significance to be assessed by the qualified investigator (QI). Participants who are taking allowed prescribed medications must agree to maintain their current method and dosing regimen during the course of the study unless recommended by their physician.
  • Known Type I or Type II diabetes, including women who previously have had gestational diabetes.
  • Use of antibiotics within 2 weeks of enrollment
  • Metabolic diseases and/or chronic gastrointestinal diseases (IBS, Crohns etc.)
  • Allergy to ingredients included in investigational product, placebo or standardized meal
  • Participants restricted to a vegetarian or vegan diet
  • Intolerance to lactose or gluten
  • Individuals who are averse to venous catheterization or capillary blood sampling
  • Currently active smokers (or using other tobacco products, and e-cigarettes)
  • Unstable medical conditions as determined by QI
  • Participation in other clinical research trials
  • Individuals who are cognitively impaired and/or who are unable to give informed consent
  • Acute infection
  • Any other condition which in the QI's opinion may adversely affect the individual's ability to complete the study or its measures or which may pose significant risk to the individual
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    Water with amino acids and chromium

    The carbonated water with a proprietary blend of five amino acids and chromium picolinate is consumed with a standardized test meal to study its effects on glucose and insulin responses.

    Dietary Supplement: Carbonated water with amino acids and chromium

  • Placebo comparator
    Carbonated water

    The placebo carbonated water is consumed with a standardized test meal to study its effects on glucose and insulin responses.

    Dietary Supplement: Placebo Carbonated Water

Interventions

  • Dietary supplementCarbonated water with amino acids and chromium

    The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes

  • Dietary supplementPlacebo Carbonated Water

    The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes

06

What researchers measure

Primary outcomes

  1. The three-hour incremental area under the curve (iAUC) for capillary blood glucose, 0-180 minutes

    The incremental area under the curve for capillary blood glucose will be measured within 180 minutes after a test meal. Blood samples will be collected at 8 time points during the 180 minutes.

    Time frame: 0, 15, 30, 45, 60, 90, 120 and 180 minutes post test meal

Secondary outcomes

  1. The three-hour iAUC for insulin, 0-180 minutes

    The incremental area under the curve for intravenous blood insulin will be measured within 180 minutes after a test meal. Blood samples will be collected at 8 time points during the 180 minutes.

    Time frame: 0, 15, 30, 45, 60, 90, 120 and 180 minutes post test meal

  2. The three hour iAUC for intravenous glucose, 0-180 minutes

    The incremental area under the curve for intravenous blood glucose will be measured within 180 minutes after a test meal. Blood samples will be collected at 8 time points during the 180 minutes.

    Time frame: 0, 15, 30, 45, 60, 90, 120 and 180 minutes post test meal

  3. The one-hour iAUC for intravenous Glucagon-like peptide 1 (GLP-1), 0-60 minutes

    The incremental area under the curve for intravenous blood GLP-1 will be measured within 60 minutes after a test meal. Blood samples will be collected at 5 time points during the 60 minutes.

    Time frame: 0, 15, 30, 45 and 60 minutes post test meal

Other outcomes

  1. The three-hour Cmax of capillary blood glucose, venous blood glucose and venous blood insulin

    Blood samples will be collected at 8 time points during the 180 minutes.

    Time frame: 0, 15, 30, 45, 60, 90, 120 and 180 minutes post test meal

  2. The Tmax (time to maximum concentration) of capillary blood glucose, venous blood glucose and venous blood insulin

    Blood samples will be collected at 8 time points during the 180 minutes.

    Time frame: 0, 15, 30, 45, 60, 90, 120 and 180 minutes post test meal

  3. The two-hour iAUC for capillary blood glucose, venous blood glucose and venous blood insulin

    Blood samples will be collected at 7 time points during the 120 minutes.

    Time frame: 0, 15, 30, 45, 60, 90 and 120 minutes post test meal

  4. The one-hour iAUC for capillary blood glucose, venous blood glucose and venous blood insulin

    Blood samples will be collected at 5 time points during the 60 minutes.

    Time frame: 0, 15, 30, 45 and 60 minutes post test meal

  5. Difference in one-hour glucose (delta-glucose at 1h) from both capillary and intravenous blood.

    A delta value will be calculated from samples collected at time=0 and time=60 minutes

    Time frame: 0 and 60 minutes post test meal

  6. Difference in two-hour glucose (delta-glucose at 2h) from both capillary and intravenous blood.

    A delta value will be calculated from samples collected at time=0 and time=120 minutes

    Time frame: 0 and 120 minutes post test meal

07

Study locations

1 site
  • Dept Experimental Medical Science, Lund University
    Lund, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03552315
Lead sponsor
DoubleGood AB
Collaborators
Lund University
Responsible party
Sponsor
First posted
Jun 11, 2018
Start date
Apr 24, 2018
Primary completion
Sep 5, 2018
Completion
Sep 5, 2018
Last update
Sep 4, 2019

Study contacts

Kristina E Andersson, PhD
principal investigator · Lund University and Aventure AB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion